Gaucher disease type 1

Gaucher disease is a lysosomal storage disorder. Lysosomes are the parts of a cell that break down and recycle used material. When the enzyme glucocerebrosidase is missing or weak, a fatty substance called glucocerebroside builds up. It collects mostly inside white blood cells called macrophages, which swell into “Gaucher cells” in the spleen, liver and bone marrow.

Type 1 is the most common form. Doctors also call it non-neuronopathic Gaucher disease, because the brain and spinal cord are usually not affected. In France, about 95 of every 100 people with Gaucher disease have type 1. Signs range from none at all to severe, and they can appear at any age from childhood to adulthood.

Doctors confirm the diagnosis with a blood test that measures the enzyme in white blood cells, or with a genetic test.

Type 1 is caused by changes in both copies of the GBA1 gene. This gene holds the instructions for the glucocerebrosidase enzyme. The changes greatly lower how well the enzyme works, so glucocerebroside and related substances build up to harmful levels inside cells.

It is inherited in an autosomal recessive pattern. Each parent usually carries one changed copy and has no symptoms. When both parents are carriers, each child has a 1 in 4 chance of having the condition.

Type 1 is more common in people of Ashkenazi (eastern and central European) Jewish heritage. It affects about 1 in 500 to 1,000 of them. It is not caused by anything a parent did, and it is not contagious. A genetic counselor can explain what a diagnosis means for brothers, sisters and other relatives.

The spleen is enlarged in more than 9 of every 10 people with type 1, and the liver often is too. Low red cells (anemia) can cause tiredness. Low platelets can cause easy bruising and a tendency to bleed.

Bone disease is common. It can cause bone pain, sudden attacks of severe pain (bone crises), thin bones and fractures. Parts of a bone can also lose their blood supply and die (osteonecrosis). Children whose disease is not treated often grow slowly and start puberty late.

Some people develop lung disease. Over time, people with type 1 also have a higher chance than other people of Parkinson disease and of some blood cancers, such as multiple myeloma. Experts still debate how large the cancer risk is.

Doctors often first notice low platelets, a large spleen, or bone problems such as osteonecrosis. These are the most common findings that lead to a diagnosis. Because the signs look like other conditions, including some blood cancers, people may see several specialists before Gaucher disease is tested for.

The key test measures the enzyme glucocerebrosidase in white blood cells from a blood sample. It needs cells that have a nucleus, so it cannot be done on plasma or red cells. Genetic testing looks for changes in both copies of the GBA1 gene. A blood marker called lyso-Gb1 (glucosylsphingosine) helps confirm the diagnosis and track treatment.

Gene results give clues about the type. A person with even one N370S change (also written N409S) does not have one of the forms that affect the brain. Doctors also check eye movements, because a person with slowed side-to-side eye movements is often reclassified as type 3.

Gaucher disease is not on the national U.S. newborn screening list, but as of a 2025 report six states screened all babies: Illinois, Missouri, New Jersey, Tennessee, Oregon and New Mexico. In New Jersey, 438,515 babies were screened from July 2019 to December 2023. Fourteen were confirmed to have type 1, and two more were suspected type 1.

Not everyone with type 1 needs treatment right away. People without symptoms may be followed with regular checkups. French national guidance bases the decision on symptoms, blood counts, the size of the spleen and bone disease. It says an expert team should discuss treatment for every child who has symptoms. Once treatment starts, it usually continues for life.

Enzyme replacement therapy gives a lab-made version of the missing enzyme through a vein, usually every two weeks, in a clinic or at home. In the United States, three enzyme medicines are approved for type 1: imiglucerase (Cerezyme), velaglucerase alfa (VPRIV) and taliglucerase alfa (Elelyso). Imiglucerase and velaglucerase alfa are approved in the European Union.

Substrate reduction therapy is a pill that lowers how much of the fatty substance the body makes. Eliglustat (Cerdelga) is approved in the United States for adults with type 1. In the European Union, it is also approved for some children. They must be 6 or older, weigh at least 15 kg and have disease controlled on enzyme therapy. A CYP2D6 gene test decides whether eliglustat can be used and at what dose. An older pill, miglustat (Zavesca), is used for some adults who cannot have enzyme therapy or eliglustat.

With treatment, anemia usually clears after 12 to 24 months, and the spleen and liver shrink. Bones improve more slowly, and bone density can take years to recover. Removing the spleen (splenectomy) is no longer recommended except in special cases.

Before enzyme therapy, a donor stem cell transplant was used for severe Gaucher disease. The donor’s cells make new macrophages that carry the working enzyme. In a 1995 European report, five people with type 1 whose donor cells took hold lost their symptoms. But transplant carried a real risk of death. The same report covered 63 people transplanted for several storage disorders. About 1 in 10 died from transplant complications when a matched brother or sister was the donor. With a less well-matched donor, 1 in 5 to 1 in 4 died. Enzyme therapy replaced transplant in wealthier countries in the 1990s.

Today, experts judge that transplant’s risks usually outweigh its benefits when enzyme therapy or pills are available. French national guidance does not use it for type 1. A 2017 review found no clinical trial comparing transplant with these medicines. Some centers, including in Thailand, have used transplant for children because lifelong enzyme therapy is costly and hard to keep up in their setting.

Gene therapy is being studied. FLT201 is a one-time treatment that uses a modified virus to carry a working copy of the gene. As of September 2026, a phase 3 trial was enrolling adults with type 1 in 10 countries. It is not approved.

For most people who need it, treatment is lifelong. People on enzyme therapy have an infusion every two weeks, in a clinic or at home. People on pills take them by mouth each day and check new medicines with their care team, because some medicines interact with eliglustat.

Regular checkups track blood markers and the size of the spleen and liver, along with bone scans. French guidance checks blood counts and blood markers every six months at first, then once or twice a year once things are stable. Scans are done about yearly at first and then every 3 to 4 years.

Getting a diagnosis can take a long time, because the early signs look like many other problems. In a 2024–2025 survey of 142 people affected by Gaucher disease in 40 countries, 58% said they waited more than a year. Once a family’s gene changes are known, brothers and sisters can be tested so treatment can start early if they need it.

Pregnancy is planned with the care team. French guidance says the pills are not used during pregnancy or breastfeeding, and enzyme therapy is preferred then.

Most people with type 1 are treated with medicine, not a transplant, so a donor is not part of usual care.

When a transplant has been used for Gaucher disease, the cells came from another person. Published reports describe matched brothers or sisters, a parent, unrelated volunteers, half-matched relatives and umbilical cord blood. Some donors were relatives who carry one changed gene copy.

A shortage of registry donors is not what limits care for type 1. Joining a registry still helps the many patients with other conditions who need an unrelated donor.

Type 1 varies a lot. Some people never have symptoms, while others have severe disease from childhood. Symptoms that start early usually mean more severe disease.

Treatment has changed the outlook. Enzyme therapy and pills usually bring major improvements within one to five years. Starting early can prevent some rare but permanent problems, such as scarring of the spleen, liver or lungs and lasting joint damage after bone injury.

The best-known life expectancy estimate is from 2008. It came from a large international registry, and most of the people in it had gone untreated for most of their lives. People whose spleen had been removed had shorter estimated lives. A 2025 expert review says that with early treatment, life expectancy for type 1 is nearing that of the general population.